Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | KHK | P50053 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23573284 | 0.82 | RAB9A (0.42) | MEN1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL23573483 | 0.78 | MEN1 (0.33) | KDM4EMEN1KMT2A | |
| SCHEMBL23573508 | 0.71 | NPC1 (0.33) | — | |
| SCHEMBL23573509 | 0.71 | NPC1 (0.33) | — | |
| SCHEMBL23462310 | 0.71 | TRPC5 (0.44) | POLB | |
| SCHEMBL23490551 | 0.70 | EPHX1 (0.34) | KDM4EPOLBTAAR1SMN1; SMN2 | |
| SCHEMBL23573210 | 0.70 | EPHX1 (0.34) | KDM4EPOLBTAAR1SMN1; SMN2 | |
| SCHEMBL23489936 | 0.70 | EPHX1 (0.36) | SMN1; SMN2 | |
| SCHEMBL23573516 | 0.70 | EPHX1 (0.36) | SMN1; SMN2 | |
| SCHEMBL23490549 | 0.69 | EGLN1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ADORA2A, ENTPD1 | KDM4E 2880/4885MEN1 1145/4885KMT2A 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.